Table 2.
Adjusted ACWY-B/ACWY-A GMT ratios for MenA, MenC, MenW-135, and MenY titers 1 month after vaccination, with the GlaxoSmithKline rSBA assay (ATP cohort for immunogenicity)
| Antibody | ACWY-Ba |
ACWY-A |
Adjusted GMT ratio (ACWY-B/ACWY-A) (95% CI)b | ||
|---|---|---|---|---|---|
| N | Adjusted GMT | N | Adjusted GMT | ||
| MenA | 298 | 5,195.3 | 302 | 4,997.0 | 1.04 (0.92–1.17)c |
| MenC | 342 | 6,874.5 | 346 | 5,988.0 | 1.15 (0.96–1.37)c |
| MenW-135 | 327 | 9,202.5 | 338 | 10,115.0 | 0.91 (0.80–1.04)c |
| MenY | 353 | 10,339.0 | 358 | 11,757.9d | 0.88 (0.78–0.99)c |
a
ACWY-A, subjects vaccinated with MenACWY-TT lot A; ACWY-B, subjects vaccinated with MenACWY-TT lot B; N, number of subjects with both pre- and postvaccination results available; adjusted GMT, geometric mean antibody titer adjusted for country and baseline titer.
b
CI, confidence interval. The ANCOVA model included adjustment for country and baseline titer, with pooled variance.
c
The upper limit of the 95% CI is below the noninferiority limit of 2.
d
Statistically significantly higher value in the ACWY-A group than in the ACWY-B group (exploratory analysis).